EUVIMEDEUVIMED entdecken
Crossref

DPP4‐Driven Ferroptosis Promotes Senescence: Galangin as a Therapeutic Agent for Age‐Related Bone Loss

Hongming Zhou, Xiaoxi Liu, Hengren Li, Heng Yang, Xingang Cui iD

Drug Development Research · 2026

DOI: 10.1002/ddr.70295 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, 2026. Verfasst von Hongming Zhou und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Spine Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China. Hauptthemen laut MEDLINE: Ferroptosis, Flavonoids, Dipeptidyl Peptidase 4, Osteoporosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Natural Science Foundation of Shandong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Senile osteoporosis is driven by bone marrow stromal cell (BMSC) senescence. Ferroptosis, an iron‐dependent cell death pathway, is implicated in aging. The natural flavonoid galangin possesses anti‐aging properties, yet its effects on ferroptosis and BMSC senescence are unknown. Natural aging and d ‐galactose‐induced aging models were used, with galangin supplementation. Bone mass was assessed via micro‐computed tomography and histomorphometry. Senescence markers (P21, SA‐β‐gal, NAD+) and ferroptosis regulators (GPX4, GSH/GSSG) were measured. BMSC senescence was induced by d ‐galactose or serial passaging. Effects of galangin on senescence, ferroptosis, osteogenic differentiation, and dipeptidyl peptidase‐4 (DPP4) signaling were evaluated. Galangin significantly attenuated bone loss and reduced senescence markers in both aging mouse models. Ferroptosis was activated in senescent BMSC. Galangin suppressed ferroptosis, rescued senescence phenotypes, and restored osteogenic differentiation capacity. Mechanistically, galangin inhibited DPP4 nuclear translocation and disrupted its interaction with NADPH oxidase NOX1, thereby blocking reactive oxygen species‐dependent ferroptosis signaling without altering total DPP4 expression. Galangin ameliorates Senile osteoporosis by specifically inhibiting DPP4 nuclear translocation and its interaction with NOX1, thereby suppressing ferroptosis, rescuing BMSC senescence, and restoring osteogenic function. This identifies galangin as a promising agent against skeletal aging.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FerroptosisFlavonoidsDipeptidyl Peptidase 4OsteoporosisAnimalsCellular SenescenceMiceMesenchymal Stem CellsOsteogenesisAgingHumansMice, Inbred C57BLCell DifferentiationSignal Transduction

Stichwörter der Autor:innen

boneferroptosisgalanginsenescence

Substanzen

galanginFlavonoidsDipeptidyl Peptidase 4

Autor:innen und Institutionen

  • Department of Spine Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
  • Department of Spinal Surgery, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Jinan, China.
  • Department of Spine Surgery, Linyi Central Hospital, Linyi, Shandong, China.
  • College of First Clinical Medical, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.
  • Department of Spine Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, China.

ORCID-Profile: Xingang Cui

Förderung

  • Natural Science Foundation of Shandong Province

Zitieren

APA

Zhou, H., Liu, X., Li, H., Yang, H., & Cui, X. (2026). DPP4‐Driven Ferroptosis Promotes Senescence: Galangin as a Therapeutic Agent for Age‐Related Bone Loss. Drug Development Research. https://doi.org/10.1002/ddr.70295

Vancouver

Zhou H, Liu X, Li H, Yang H, Cui X. DPP4‐Driven Ferroptosis Promotes Senescence: Galangin as a Therapeutic Agent for Age‐Related Bone Loss. Drug Development Research. 2026. doi:10.1002/ddr.70295

BibTeX
@article{Zhou2026,
  author = {Zhou, Hongming and Liu, Xiaoxi and Li, Hengren and Yang, Heng and Cui, Xingang},
  title = {DPP4‐Driven Ferroptosis Promotes Senescence: Galangin as a Therapeutic Agent for Age‐Related Bone Loss},
  journal = {Drug Development Research},
  year = {2026},
  doi = {10.1002/ddr.70295}
}
Kostenlos starten →